# EDGAR Filing Document

**Accession Number:** 0001922335
**File Stem:** 0000000000-23-000153
**Filing Date:** 2023-1
**Character Count:** 11106
**Document Hash:** 9e09f4240cb20a25129ab3f07fbdd280
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-000153.hdr.sgml**: 20231027

**ACCESSION NUMBER**: 0000000000-23-000153

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230105

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Syra Health Corp
- **CENTRAL INDEX KEY:** 0001922335
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-EMPLOYMENT AGENCIES [7361]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** 1119 KEYSTONE WAY N.
- **STREET 2:** #201
- **CITY:** CARMEL
- **STATE:** IN
- **ZIP:** 46032
- **BUSINESS PHONE:** (317) 922-0922

**MAIL ADDRESS:**
- **STREET 1:** 1119 KEYSTONE WAY N.
- **STREET 2:** #201
- **CITY:** CARMEL
- **STATE:** IN
- **ZIP:** 46032
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001493152-22-030203

## Text-Extract

```

United States securities and exchange commission logo

                             January 5, 2023

       Deepika Vuppalanchi
       Chief Executive Officer
       Syra Health Corp
       1119 Keystone Way N. #201
       Carmel, IN 46032

                                                        Re: Syra Health Corp
                                                            Amendment No. 1 to
Draft Registration Statement on Form S-1
                                                            Submitted December
14, 2022
                                                            CIK No. 0001922335

       Dear Deepika Vuppalanchi:

             We have reviewed your amended draft registration statement and
have the following
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

              Please respond to this letter by providing the requested
information and either submitting
       an amended draft registration statement or publicly filing your
registration statement on
       EDGAR. If you do not believe our comments apply to your facts and
circumstances or do not
       believe an amendment is appropriate, please tell us why in your
response.

             After reviewing the information you provide in response to these
comments and your
       amended draft registration statement or filed registration statement, we
may have additional
       comments.

       Amendment No. 1 to Draft Registration Statement on Form S-1 submitted
December 14, 2022

       Cover Page

   1.                                                   We note your response
to comment 1, as well as your revised disclosure that "such Class
                                                        B holders shall
continue to have voting control until they hold under % of the voting
                                                        power of our
outstanding capital stock." Please revise to disclose the number of Class B
                                                        shares, and the
percentage of your total common stock outstanding represented by such
                                                        shares, that the Class
B holders need to hold to continue to control general corporate
                                                        matters. Please make
conforming changes to your Selling Stockholder Prospectus cover
                                                        page and also include
similar disclosure in your risk factor on page 21. Additionally, in
                                                        such risk factor,
please disclose the total percentage of voting power that such Class B
                                                        holders will hold
following the offering, as you only disclose there the anticipated
 Deepika Vuppalanchi
Syra Health Corp
January 5, 2023
Page 2
      percentage of Class B common stock and total outstanding stock held after
the offering.
2.    We note your response to comment 18. Please revise the IPO Prospectus
cover page to
      state that the offering is contingent on the listing of your Class A
common stock on
      Nasdaq, if true, as your disclosure on page 73 states that "we will not
complete this
      offering unless we are so listed."
3.    We note your revised disclosure on the Selling Stockholder Prospectus
cover page that
      "[t]he selling stockholders will not make any sales of their shares until
such time as our
      shares are listed on a national securities exchange," thereby indicating
that sales in
      the resale offering will not take place until after the completion of
your initial public
      offering and your listing. Please reconcile this with your disclosure on
the IPO Prospectus
      cover page that "[s]ales of the shares of our Class A common stock
registered in this
      prospectus and the Selling Stockholder Prospectus may result in two
offerings taking
      place concurrently . . . ," and make conforming changes as appropriate.
Prospectus Summary, page 1

4.    We note your response to comment 12. Please prominently disclose here and
at the
      beginning of the Business section that the Indiana Family and Social
Services
      Administration "accounted for approximately 98% of revenues and 86% of
accounts
      receivable at December 31, 2021," as you disclose on page 19.
General

5.    We note your disclosure on the Selling Stockholders Prospectus cover page
that the
      selling stockholders will sell their shares "at market prices prevailing
at the time of sale or
      at negotiated prices." In connection therewith, please include a
placeholder for the date of
      effectiveness of the IPO prospectus, as well as the IPO price, and
confirm that you will
      include such information in the Rule 424(b) prospectus filed in
connection with this resale
      offering. Refer to Instruction 2 to Item 501(b)(3) of Regulation S-K.
       You may contact Scott Stringer at 202-551-3272 or Joel Parker at
202-551-3651 if you
have questions regarding comments on the financial statements and related
matters. Please
contact Brian Fetterolf at 202-551-6613 or Erin Jaskot at 202-551-3442 with any
other questions.

                                                              Sincerely,
FirstName LastNameDeepika Vuppalanchi
                                                              Division of
Corporation Finance
Comapany NameSyra Health Corp
                                                              Office of Trade &
Services
January 5, 2023 Page 2
cc:       Jeffrey Fessler
FirstName LastName

```

### Attached PDF Documents

**Attachment 1:** `filename1`

![img-0.jpeg](img-0.jpeg)

CORPORATION FINANCE

# UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

January 5, 2023

Deepika Vuppalanchi  
Chief Executive Officer  
Syra Health Corp  
1119 Keystone Way N. #201  
Carmel, IN 46032

# **Re: Syra Health Corp**  
**Amendment No. 1 to Draft Registration Statement on Form S-1**  
**Submitted December 14, 2022**  
**CIK No. 0001922335**

Dear Deepika Vuppalanchi:

We have reviewed your amended draft registration statement and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to this letter by providing the requested information and either submitting an amended draft registration statement or publicly filing your registration statement on EDGAR. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing the information you provide in response to these comments and your amended draft registration statement or filed registration statement, we may have additional comments.

Amendment No. 1 to Draft Registration Statement on Form S-1 submitted December 14, 2022

# Cover Page

1. We note your response to comment 1, as well as your revised disclosure that 'such Class B holders shall continue to have voting control until they hold under % of the voting power of our outstanding capital stock.' Please revise to disclose the number of Class B shares, and the percentage of your total common stock outstanding represented by such shares, that the Class B holders need to hold to continue to control general corporate matters. Please make conforming changes to your Selling Stockholder Prospectus cover page and also include similar disclosure in your risk factor on page 21. Additionally, in such risk factor, please disclose the total percentage of voting power that such Class B holders will hold following the offering, as you only disclose there the anticipated

Deepika Vuppalanchi
Syra Health Corp
January 5, 2023
Page 2

percentage of Class B common stock and total outstanding stock held after the offering.

2. We note your response to comment 18. Please revise the IPO Prospectus cover page to state that the offering is contingent on the listing of your Class A common stock on Nasdaq, if true, as your disclosure on page 73 states that "we will not complete this offering unless we are so listed."
3. We note your revised disclosure on the Selling Stockholder Prospectus cover page that "[t]he selling stockholders will not make any sales of their shares until such time as our shares are listed on a national securities exchange," thereby indicating that sales in the resale offering will not take place until after the completion of your initial public offering and your listing. Please reconcile this with your disclosure on the IPO Prospectus cover page that "[s]ales of the shares of our Class A common stock registered in this prospectus and the Selling Stockholder Prospectus may result in two offerings taking place concurrently . . . ," and make conforming changes as appropriate.

Prospectus Summary, page 1

4. We note your response to comment 12. Please prominently disclose here and at the beginning of the Business section that the Indiana Family and Social Services Administration "accounted for approximately 98% of revenues and 86% of accounts receivable at December 31, 2021," as you disclose on page 19.

General

5. We note your disclosure on the Selling Stockholders Prospectus cover page that the selling stockholders will sell their shares "at market prices prevailing at the time of sale or at negotiated prices." In connection therewith, please include a placeholder for the date of effectiveness of the IPO prospectus, as well as the IPO price, and confirm that you will include such information in the Rule 424(b) prospectus filed in connection with this resale offering. Refer to Instruction 2 to Item 501(b)(3) of Regulation S-K.

You may contact Scott Stringer at 202-551-3272 or Joel Parker at 202-551-3651 if you have questions regarding comments on the financial statements and related matters. Please contact Brian Fetterolf at 202-551-6613 or Erin Jaskot at 202-551-3442 with any other questions.

Sincerely,

Division of Corporation Finance
Office of Trade & Services

cc: Jeffrey Fessler